IL-23 inhibitors for cutaneous psoriasis like guselkumab, risankizumab, and tildrakizumab are promising, though reports are limited (Table I).8, 9, 10, 11, 12 Including our 2 patients, a total of 10 patients with ICI-associated psoriasis have been treated with risankizumab (n = 6) and guselkumab (n = 4). This evidence concerns the gene IL37 and psoriasis.